Related Experiment Video
Updated: Oct 17, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Identification of immunization-related new prognostic biomarkers for papillary renal cell carcinoma by integrated
Ping Wu1, Tingting Xiang2, Jing Wang3
1Department of Anesthesiology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, China.
Background:
Despite papillary renal cell carcinoma (pRCC) being the second most common type of kidney cancer, the underlying molecular mechanism remains unclear. Targeted therapies in the past have not been successful because of the lack of a clear understanding of the molecular mechanism. Hence, exploring the underlying mechanisms and seeking novel biomarkers for pursuing a precise prognostic biomarker and appropriate therapies are critical.
Material And Methods:
In our research, the differentially expressed genes (DEGs) were screened from the TCGA and GEO databases, and a total of 149 upregulated and 285 downregulated genes were sorted. This was followed by construction of functional enrichment and protein-protein interaction (PPI) network, and then the top 15 DEGs were selected for further analysis. The P4HB gene was chosen as our target gene by repetitively validating multiple datasets, and higher levels of P4HB expression predicted lower overall survival (OS) in patients with pRCC.
Results:
We found that P4HB not only connects with immune cell infiltration and co-expression with PD-1, PD-L2, and CTLA-4, but also has a strong connection with the newly discovered hot gene, TOX.
Conclusion:
We speculate that P4HB is a novel gene involved in the progression of pRCC through immunomodulation.
Insights
The P4HB gene may play a role in papillary renal cell carcinoma (pRCC) progression by influencing the immune system. Higher P4HB expression correlates with poorer survival in pRCC patients, suggesting it as a potential biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Papillary renal cell carcinoma (pRCC) is a common kidney cancer with unclear molecular mechanisms.
- Previous targeted therapies for pRCC have been unsuccessful due to limited understanding of its molecular basis.
- Identifying novel biomarkers and understanding pRCC progression are crucial for developing effective treatments.
Purpose of the Study:
- To investigate the molecular mechanisms underlying papillary renal cell carcinoma (pRCC).
- To identify potential prognostic biomarkers for pRCC.
- To explore novel therapeutic targets for pRCC.
Main Methods:
- Screened differentially expressed genes (DEGs) from TCGA and GEO databases.
- Constructed functional enrichment and protein-protein interaction (PPI) networks.
- Selected and validated the P4HB gene across multiple datasets.
Main Results:
- Identified 149 upregulated and 285 downregulated genes in pRCC.
- Selected P4HB as a key gene, with higher expression linked to lower overall survival (OS) in pRCC patients.
- Found P4HB correlates with immune cell infiltration, PD-1, PD-L2, CTLA-4, and the gene TOX.
Conclusions:
- P4HB is a potential novel gene involved in pRCC progression.
- P4HB may exert its influence through immunomodulation in pRCC.
- P4HB could serve as a prognostic biomarker for pRCC.
